Gilead’s Kite Acquires Interius for $350M to Advance In Vivo CAR T-Cell Therapy Platform

Foster City, CA, August 21, 2025 (Reuters) -- Kite Pharma, a Gilead subsidiary, will acquire Interius BioTherapeutics for $350 million to advance in vivo CAR T-cell therapy platforms. Interius’s approach allows cell therapies to be generated inside the patient, eliminating the need for external cell engineering and potentially lowering costs while broadening access. The acquisition integrates Interius into Kite’s Philadelphia research team, strengthening Gilead’s long-term oncology pipeline.

Read full article here.